Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome

Published:2013-03 Issue:3 Volume:33 Page:295-303
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

McBride Ali¹,Lathon Sherrie C.²,Boehmer Leigh²,Augustin Kristan M.²,Butler Sara K.²,Westervelt Peter³

Affiliation:

1. Department of Pharmacy; Arthur G. James Cancer Hospital; The Ohio State University; Columbus Ohio

2. Department of Pharmacy; Barnes-Jewish Hospital; St. Louis Missouri

3. Division of Oncology; Washington University School of Medicine; St. Louis Missouri

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/phar.1198/fullpdf

Reference20 articles.

1. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review;Coiffier;J Clin Oncol,2008

2. Tumour lysis syndrome: new therapeutic strategies and classification;Cairo;Br J Haematol,2004

3. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma;Pui;J Clin Oncol,2001

4. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (groupe d'etude des lymphomes de l'adulte trial on rasburicase activity in adult lymphoma) study;Coiffier;J Clin Oncol,2003

5. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study;Cortes;J Clin Oncol,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers;Cell Reports Medicine;2023-12

2. Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices;Journal of Oncology Pharmacy Practice;2023-08-10

3. A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome;Leukemia & Lymphoma;2023-02-23

4. Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase;Seminars in Nephrology;2022-11

5. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies;Clinical Lymphoma Myeloma and Leukemia;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3